



HIV-1 Vpr Causes Synaptodendritic Damage in Neurons

Journal of Health Disparities Research and Practice

Volume 9
Issue 5 *Special Issue - NIDDK STEP UP*

Article 99

© Center for Health Disparities Research, School of Public Health, University of Nevada, Las Vegas

2016

HIV-1 Vpr Causes Synaptodendritic Damage in Neurons

María A. Torres Rivera

Richard Noel, Jr., PhD, *Ponce Health Sciences University-Ponce Research Institute*

Bethzaly Velázquez-Pérez, *Ponce Health Sciences University*

See next page for additional authors

Follow this and additional works at: <https://digitalscholarship.unlv.edu/jhdrp>



Part of the [Bilingual, Multilingual, and Multicultural Education Commons](#), [Community College Leadership Commons](#), [Higher Education Commons](#), [Immune System Diseases Commons](#), [Public Health Commons](#), [Translational Medical Research Commons](#), and the [Virus Diseases Commons](#)

Recommended Citation

Torres Rivera, María A.; Noel, Jr., PhD, Richard; Velázquez-Pérez, Bethzaly; and Martínez-Orengo, MS, Neysha (2016) "HIV-1 Vpr Causes Synaptodendritic Damage in Neurons," *Journal of Health Disparities Research and Practice*: Vol. 9: Iss. 5, Article 99.

Available at: <https://digitalscholarship.unlv.edu/jhdrp/vol9/iss5/99>

This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/or on the work itself.

This Article has been accepted for inclusion in *Journal of Health Disparities Research and Practice* by an authorized administrator of Digital Scholarship@UNLV. For more information, please contact digitalscholarship@unlv.edu.

HIV-1 Vpr Causes Synaptodendritic Damage in Neurons

Abstract

HIV weakens the immune system by infecting and destroying T-cells, leaving the body vulnerable to infection and the development of AIDS. Conventional treatments for HIV, such as combined anti-retroviral therapy (cART), fail to prevent the development of HIV-associated neurocognitive disorder (HAND). Neurological dysfunction has been directly related to the invasion of HIV in the central nervous system (CNS). HIV produces neurotoxic proteins, such as the Viral Protein R (Vpr), which contribute to HAND. Astrocytes are the most abundant cells in the brain and an important HIV target. We hypothesize that astrocytes expressing Vpr will cause neuronal damage in our co-culture system. Primary astrocytes were transfected with Vpr plasmid or control (pEGFP or mock) using electroporation. Astrocytes were then co-cultured with cortical neurons. At 48 and 72 hours we collected the primary astrocytes to confirm the Vpr expression via western blot analysis. We then measured structural damage in the neurons using immunofluorescence for cytoskeletal (MAP2, f-actin) and synaptic (synaptophysin) damage. Preliminary results showed strong staining of filamentous actin and MAP2 with weak detection of synaptophysin. The positive control for neurotoxicity (2.8 μ M acrylamide) showed substantial damage to the cellular structure. Results for Vpr expression are pending. After confirming that the immunofluorescence assays are working with our controls, we expect to detect any synaptodendritic damage in the neurons caused by Vpr in our upcoming experiments.

Keywords

: synaptodendritic; neurocognitive; synaptophysin; MAP2; cART

Authors

María A. Torres Rivera; Richard Noel, Jr., PhD; Bethzaly Velázquez-Pérez; and Neysha Martínez-Orengo, MS



Journal of Health Disparities Research and Practice
Volume 9, Special Edition 1, Summer 2016, pp. 138
© 2011 Center for Health Disparities Research
School of Community Health Sciences
University of Nevada, Las Vegas

HIV-1 Vpr Causes Synaptodendritic Damage in Neurons

María A. Torres Rivera

Richard Jr. Noel, PhD, Ponce Health Sciences University/Ponce Research Institute

Bethzaly Velázquez-Pérez, Ponce Health Sciences University

Neysha Martínez-Orengo, MS, Ponce Health Sciences University

Coordinating Center: University of Nevada Las Vegas

ABSTRACT

HIV weakens the immune system by infecting and destroying T-cells, leaving the body vulnerable to infection and the development of AIDS. Conventional treatments for HIV, such as combined anti-retroviral therapy (cART), fail to prevent the development of HIV-associated neurocognitive disorder (HAND). Neurological dysfunction has been directly related to the invasion of HIV in the central nervous system (CNS). HIV produces neurotoxic proteins, such as the Viral Protein R (Vpr), which contribute to HAND. Astrocytes are the most abundant cells in the brain and an important HIV target. We hypothesize that astrocytes expressing Vpr will cause neuronal damage in our co-culture system. Primary astrocytes were transfected with Vpr plasmid or control (pEGFP or mock) using electroporation. Astrocytes were then co-cultured with cortical neurons. At 48 and 72 hours we collected the primary astrocytes to confirm the Vpr expression via western blot analysis. We then measured structural damage in the neurons using immunofluorescence for cytoskeletal (MAP2, f-actin) and synaptic (synaptophysin) damage. Preliminary results showed strong staining of filamentous actin and MAP2 with weak detection of synaptophysin. The positive control for neurotoxicity (2.8 μ M acrylamide) showed substantial damage to the cellular structure. Results for Vpr expression are pending. After confirming that the immunofluorescence assays are working with our controls, we expect to detect any synaptodendritic damage in the neurons caused by Vpr in our upcoming experiments.

Key Words: synaptodendritic, neurocognitive, synaptophysin, MAP2, cART

ACKNOWLEDGEMENTS

The STEP-UP HS program is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, Grant number: 1R25DK098067-01.